Trisomy 21 is the most well-known genetic condition. Named after John Langdon Down, the English physician who first published a description of the condition in 1866; Trisomy 21 is also known as ‘Down syndrome’. The condition was classified as a chromosomal condition in 1959 by the French physician Jerome Lejeune.
Trisomy 21 occurs when a person has 3 copies of chromosome 21 instead of the typical pair, making the total chromosomal count 47 instead of 46. The additional chromosomal copy can be passed during fertilization either from the maternal or the paternal gamete (reproductive cell). Less than 10% of Down syndrome cases are due to a paternal non-disjunction (uneven division of chromosomes) event1,2. The rest are maternal, as increased maternal age increases the chances of non-disjunction events and subsequently, having a baby with Down syndrome1. The extra chromosome can be a whole chromosomal copy, a partial copy, or a mosaic trisomic form (some cells carry 3 chromosome 21 copies and other carry 2). Mosaicism is the least common form of Down syndrome, and partial forms due to translocation (chromosomes are arranged in the wrong order) are the second least common1. The latter is the only form of Down syndrome that can be inherited.
The additional chromosomal material affects the range of developmental and physical characteristics associated with Down syndrome. These may include – to different degrees – low muscle tone, small stature, upward slant to the eyes, and mild to moderate cognitive delays1,3,4. Children with Down syndrome reach developmental milestones later than typically developing children. Early intervention services, such as physical, occupational and speech therapies during the first years of life are imperative to optimize a child’s development3,4. Approximately 50% of people with Trisomy 21 are born with a heart defect; and have an increased risk for respiratory, hearing and vision problems, Alzheimer’s disease, thyroid conditions and childhood leukemia – but are less likely to develop solid tumor cancers3,5,6. Interestingly, some research shows that people with Down syndrome are also more likely to recover from heart defects and childhood leukemia than people without Down syndrome3.
In the US, 1 in 700 children is born with Down syndrome1. The estimated worldwide incidence is between 1 in 1,000 and 1 in 1,100 live births7. As Down syndrome is the most common genetic condition during pregnancy, there are multiple prenatal screening tests for pregnant women. These screening tests check for the chance of the fetus having a genetic condition. First and second trimester screening tests, that include biochemical testing, Nuchal Translucency (NT) measurement and ultrasounds have a 95% combined sensitivity, with a 5% False Positive Rate (FPR: reporting an unaffected pregnancy as affected)8. Non-Invasive Prenatal Testing (NIPT), which analyses genetic material from the pregnancy, has over 99% sensitivity, with an FPR of 0.001%9. All positive (affected) screening tests, including NIPT, should be confirmed with a diagnostic procedure like amniocentesis. Even though the chance of having a baby with Down syndrome – or any autosomal trisomy – increases with maternal age, most children with Down syndrome are born to women younger than 35 years old as birth rates are higher in younger women1. Consequently, prenatal screening of all pregnancies is recommended and should be offered, as prospective parents can gather useful information about the health of their baby, and arrange for any necessary clinical care as early as possible. The choice to undertake such screening and diagnostic tests, and all decisions regarding the pregnancy are individual ones that only the couple can take.
Trisomy 21 was recognized as ‘Mongolian Idiocy’ or ‘Mongolism’ before being renamed and accepted as ‘Down syndrome’ by the World Health Organization in 1965. During the first half of the twentieth century, children with Down syndrome were placed in institutions shortly after birth. The end of this practice, and the advancements in clinical care, saw the average lifespan of a person with Down syndrome rising from 25 to 60 years old3,6. Nowadays, there are special guidelines in place for treatment of newborns with disabilities and federal laws enforcing education for all children with disabilities. People with Down syndrome can receive graduate and postgraduate degrees, have jobs and live independently. The social, clinical and educational advancements were brought about by parent-driven groups who took action, spread awareness and demanded a level playing field for their children.
How each family takes on a Down syndrome diagnosis is a personal and intimate decision. The medical professionals’ role is to accurately and impartially provide the parents with all necessary information about the condition and the severity of each individual case, and society’s role is to be an inclusive and unbiased place for everyone.
NIPT results, possible next steps and clinical management should always be fully discussed with your healthcare provider. VERACITY and VERAgene both detect Trisomy 21, amongst other common genetic disorders, from the 10th week of pregnancy. To learn more please visit www.nipd.com
Malone F et al. (2005) ‘First-trimester or second-trimester screening, or both, for Down’s syndrome. First and Second-Trimester Evaluation of Risk (FASTER) Research Consortium’. New England Journal of Medicine; 353(19):2001-2011.
Mackie FL et al. (2017) ‘The accuracy of cell-free fetal DNA-based non-invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis’. BJOG, 2017;124:32-46.
NIPD Genetics values your interest in NIPD Genetics, its products and its services. NIPD Genetics takes the protection of your data seriously.
You may contact NIPD Genetics Public Company Ltd at NIPD Genetics Public Company Ltd Neas Engomis 31 Engomi, Nicosia 2409, Cyprus
NIPD Genetics Data Protection Officer can be reached at email@example.com
Type of personal information NIPD Genetics may collect through its Sites
The ways by which NIPD Genetics collects, uses or shares such information
Steps NIPD Genetics takes to protect its sites’ users personal information
This page informs you of our policies regarding the collection, use, and disclosure of personal data when you use our Sites and the choices you have associated with that data.
Type of personal information NIPD Genetics may collect through its Sites
Information Collection And Use
We collect several different types of information for various purposes to provide and improve our Sites and services to you.
While using NIPD Genetics Sites, you may be asked to provide NIPD Genetics certain personally identifiable information that can be used to contact or identify you ("Personal Information"). Personal Information that might be used to identify you includes, but is not limited to:
First name and last name
Address, State, Province, ZIP/Postal code, City
If you send us a query via our Contact us form, your email address, the content and any follow up emails are retained indefinitely.
Cookies and Usage Data
We may also collect information how the Sites are accessed and used ("Usage Data"). This Usage Data may include information such as your computer's Internet Protocol address (e.g. IP address), browser type, browser version, the pages of our Sites that you visit, the time and date of your visit, the time spent on those pages, unique device identifiers and other diagnostic data.
Tracking & Cookies Data
Cookies are files with small amount of data which may include an anonymous unique identifier. Cookies are sent to your browser from a website and stored on your device. Tracking technologies also used are beacons, tags, and scripts to collect and track information and to improve and analyze our Sites.
You can instruct your browser to refuse all cookies or to indicate when a cookie is being sent. However, if you do not accept cookies, you may not be able to use some portions of our Sites.
Examples of Cookies we use:
Session Cookies. We use Session Cookies to operate our Sites.
Preference Cookies. We use Preference Cookies to remember your preferences and various settings.
Security Cookies. We use Security Cookies for security purposes.
Visitor behavior cookies. To understand how visitors use and navigate the Sites
Keyword cookies. To understand how visitors discover the Sites.
Use of Data
www.nipd.com uses the collected data for various purposes:
To provide and maintain the Sites
To notify you about changes to our Sites
To allow you to participate in interactive features of our Sites when you choose to do so
To provide customer care and support
To provide analysis or valuable information so that we can improve the Sites
To monitor the usage of the Sites
To detect, prevent and address technical issues
Transfer of Data
Your information, including personal data, may be transferred to — and maintained on — computers located outside of your province, country or other governmental jurisdiction where the data protection laws may differ than those from your jurisdiction.
If you are located outside Cyprus and choose to provide information to us, please note that we transfer the data, including personal data, to Cyprus and process it there.
Disclosure of Data
NIPD Genetics complies with the protection of personal data regulation and will not sale or trade your personal data.
NIPD Genetics may disclose your personal data in the good faith belief that such action is necessary to:
To comply with a legal obligation
To protect and defend the rights or property of www.nipd.com
To prevent or investigate possible wrongdoing in connection with the Sites
To protect the personal safety of users of the Sites or the public
To protect against legal liability
Security of Data
The security of your data is important to us, but remember that no method of transmission over the Internet, or method of electronic storage is 100% secure. While we strive to use commercially acceptable means to protect your Personal Data, we cannot guarantee its absolute security.
We may employ third party companies and individuals to facilitate, maintain or operate our Sites ("Service Providers"), to provide the SItes on our behalf, to perform service-related services or to assist us in analyzing how our Sites is used.
These third parties have access to your Personal Data only to perform these tasks on our behalf and are obligated not to disclose or use it for any other purpose.
We may use third-party Service Providers to monitor and analyze the use of our Sites.
Google Analytics is a web analytics service offered by Google that tracks and reports website traffic. Google uses the data collected to track and monitor the use of our Service. This data is shared with other Google services. Google may use the collected data to contextualize and personalize the ads of its own advertising network.
Access to your personal data, correction, deletion, and Opting Out
You have the right to review, update or delete any of your personal data by sending a request at NIPD Genetics Personal Data Officer firstname.lastname@example.org
Links to Other Sites
We have no control over and assume no responsibility for the content, privacy policies or practices of any third-party sites or services.
Our Service does not address anyone under the age of 18 ("Children").
We do not knowingly collect personally identifiable information from anyone under the age of 18. If you are a parent or guardian and you are aware that your Children has provided us with Personal Data, please contact us. If we become aware that we have collected Personal Data from children without verification of parental consent, we take steps to remove that information from our servers.